Drugs Made In America Acquisition Corp. Ordinary Shares
NASDAQ:DMAAShell Companies
+$0.00 today
- Market cap
- $264.62M
- Beta
- 0.00
- P/E (TTM)
- 36.7
- EPS (TTM)
- $0.29
Volume 0.00M
Average 0.11M
DMAA Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Drugs Made In America Acquisition Corp. Ordinary SharesNASDAQ: DMAA
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow declines year over year
Q1 FY2026 financing cash flow of $100K fell 100.0% year over year, in line with the -99.8% change in trailing-twelve-month financing cash flow. Sequentially, it fell 23.4% from the prior quarter.
What to watch
Whether quarterly growth recovers from -100.0% toward the trailing-twelve-month pace of -99.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 231.69M USD
- Year-over-year change
- +133352.0%
- 1-year CAGR
- +133352.0%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 231.69M | +133352.0% |
| FY2024 | 2024-12-31 | 173.62K | — |
Financing Cash Flow vs competitors
How DMAA compares with its peers on the latest reported figures
- DMAA's LTM Mar 2026 financing cash flow of $393.16K is the 8th largest of the 10 companies compared; the peer median is $233.75M.
- Its year-over-year change of -99.8% is the 2nd highest of 3, against a peer median of -39.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
TACOUBerto Acquisition Corp. Unit | FY2025 | $301.96M | — | — | — |
| FY2025 | $301.96M | — | — | — | |
TACHTitan Acquisition Corp. | LTM Mar 2026 | $278.75M | — | — | — |
OYSEOyster Enterprises II Acquisition Corp | FY2025 | $254.43M | — | — | — |
| FY2025 | $233.75M | — | — | — | |
| LTM Mar 2026 | $121.64M | — | — | — | |
| LTM Mar 2026 | $702.26K | +21.6% | — | — | |
| LTM Mar 2026 | $393.16K | -99.8% | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| FY2025 | $0 | -100.0% | — | — | |
| Peer median (excluding DMAA) | $233.75M | -39.2% | — | — | |
Competitors are the stored peer set for DMAA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Net Income | (479) | 3.97M |
| Depreciation & Amortization | 0 | 0 |
| Deferred Income Tax | 0 | 0 |
| Stock-Based Compensation | 0 | 0 |
| Change in Working Capital | 132 | 138.85K |
| Accounts Receivables | 0 | 0 |
| Inventory | 0 | 0 |
| Accounts Payables | 0 | 144.9K |
| Other Working Capital | 132 | (6.05K) |
| Other Non-Cash Items | (171.92K) | (4.65M) |
| Operating Cash Flow | (295) | (539.19K) |
| Capital Expenditures | 5 | 0 |
| Acquisitions (Net) | 0 | 0 |
| Purchases of Investments | 0 | 0 |
| Sales of Investments | 0 | 0 |
| Other Investing Activities | 0 | (231.15M) |
| Investing Cash Flow | 0 | (231.15M) |
| Debt Repayment | 502.21K | (900K) |
| Common Stock Issued | (328.6K) | 232.05M |
| Common Stock Repurchased | 0 | 0 |
| Dividends Paid | 0 | 0 |
| Other Financing Activities | 1 | 543.97K |
| Financing Cash Flow | 173.62K | 231.69M |
| Effect of Forex Changes | 0 | 0 |
| Net Change in Cash | 1.35K | 4.79K |
| Free Cash Flow | (295) | (539.19K) |
Drugs Made In America Acquisition Corp. Ordinary Shares
NASDAQ:DMAA
Intrinsic Alpha fair value
Locked
Current Price
$10.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.